Palma-Zamora Isaac, Sood Akshay, Dabaja Ali A
Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
Transl Androl Urol. 2017 Nov;6(Suppl 5):S767-S773. doi: 10.21037/tau.2017.04.25.
Commonly utilized as a third-line therapy for erectile dysfunction (ED) management, the penile prostheses have become a staple treatment for ED refractory to pharmacological interventions. There is however a paucity of data in the literature pertaining to short-term adverse outcomes following penile prosthesis surgery. We thus sought to leverage the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) to evaluate such outcomes within 30 days of surgery in these patients. We hypothesized that such data will lead to a more informed patient-physician consultation.
Relying on the ACS-NSQIP database [2005-2013], patients undergoing penile prosthesis placement were identified utilizing the Current Procedural Terminology (CPT) codes: 54400, 54401, 54405, 54406, 54407, 54408, 54410, 54411, 54416 and 54417. Outcomes assessed included system-wise categorized complications, length-of-stay (LOS), and re-intervention, readmission and 30-day mortality rates. Descriptive statistics were used to analyze available data. Multivariate analysis could not be performed due to small sample size.
Overall, 98 cases of patients who underwent surgery for penile prosthesis placements between the years 2005 and 2013 were reported by the ACS-NSQIP affiliated hospitals. The median age was 65 years (interquartile range, 58-70 years). The overall 30-day complication rate was 11.3% (n=11); 5 of the 11 complications were infectious in etiology, and three were a postoperative blood transfusion event. The median LOS was 1 day. One (1.0%) patient needed to return to the operating room, two patients (2.6%) were readmitted and there was one (1.0%) death within 30 days of the original surgery.
Surgery for penile prosthesis appears to be a safe operation despite the routinely advanced age of the patients requiring it. Complications in the immediate postoperative setting are usually infectious. This data can be used in the clinical setting for a more informed patient-physician discussion and patient expectation management.
阴茎假体通常作为勃起功能障碍(ED)管理的三线治疗方法,已成为药物干预难治性ED的主要治疗手段。然而,文献中关于阴茎假体手术后短期不良后果的数据很少。因此,我们试图利用美国外科医师学会国家外科质量改进计划(ACS - NSQIP)来评估这些患者术后30天内的此类结果。我们假设这些数据将有助于医患之间更明智的咨询。
依据ACS - NSQIP数据库[2005 - 2013年],利用当前操作术语(CPT)编码:54400、54401、54405、54406、54407、54408、54410、54411、54416和54417识别接受阴茎假体植入的患者。评估的结果包括系统分类的并发症、住院时间(LOS)以及再次干预、再入院和30天死亡率。采用描述性统计分析可用数据。由于样本量小,无法进行多变量分析。
总体而言,ACS - NSQIP附属医院报告了2005年至2013年间98例接受阴茎假体植入手术的患者。中位年龄为65岁(四分位间距,58 - 70岁)。总体30天并发症发生率为11.3%(n = 11);11例并发症中有5例病因是感染性的,3例是术后输血事件。中位住院时间为1天。1例(1.0%)患者需要返回手术室,2例患者(2.6%)再次入院,初次手术后30天内有1例(1.0%)死亡。
尽管需要进行阴茎假体手术的患者通常年龄较大,但该手术似乎是一种安全的手术。术后即刻的并发症通常是感染性的。这些数据可用于临床环境,以进行更明智的医患讨论和患者期望管理。